Reviewing Pulmonx (NASDAQ:LUNG) & Avita Medical (NASDAQ:RCEL)

Avita Medical (NASDAQ:RCEL – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares Avita Medical and Pulmonx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avita Medical -42.65% N/A -71.34%
Pulmonx -47.93% -98.23% -35.89%

Institutional and Insider Ownership

27.7% of Avita Medical shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 2.2% of Avita Medical shares are held by insiders. Comparatively, 7.5% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Avita Medical and Pulmonx”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avita Medical $71.61 million 6.86 -$48.59 million ($1.18) -13.25
Pulmonx $90.50 million 1.38 -$54.00 million ($1.01) -2.83

Avita Medical has higher earnings, but lower revenue than Pulmonx. Avita Medical is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Avita Medical and Pulmonx, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avita Medical 1 1 5 0 2.57
Pulmonx 1 0 3 0 2.50

Avita Medical presently has a consensus price target of $16.60, suggesting a potential upside of 6.21%. Pulmonx has a consensus price target of $7.67, suggesting a potential upside of 168.07%. Given Pulmonx’s higher probable upside, analysts clearly believe Pulmonx is more favorable than Avita Medical.

Risk and Volatility

Avita Medical has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

About Avita Medical

(Get Free Report)

AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.

About Pulmonx

(Get Free Report)

Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company’s Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.

Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.